390356-27-1

Basic information

• Product Name: 3,5-DIETHYL-4-IODO-1H-PYRAZOLE
• Synonyms: 3,5-DIETHYL-4-IODO-1H-PYRAZOLE
• CAS NO: 390356-27-1
• Molecular Formula: C7H11IN2
• Molecular Weight: 250.08
• Mol File: 390356-27-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,5-DIETHYL-4-IODO-1H-PYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIETHYL-4-IODO-1H-PYRAZOLE(390356-27-1)
• EPA Substance Registry System: 3,5-DIETHYL-4-IODO-1H-PYRAZOLE(390356-27-1)

Safety Data

• Hazardous Substances Data: 390356-27-1(Hazardous Substances Data)

Upstream product

• 2817-73-4 3,5-Diethyl-1H-pyrazole 
• 7424-54-6 3,5-heptanedione 
• 1220198-08-2 (2-bromo-ethoxy)-tert-butyl-dimethyl-silane 

Relevant articles and documents

Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors

Small-molecule inhibitors of bromodomain and extra terminal proteins (BET), including BRD2, BRD3, and BRD4 proteins have therapeutic potential for the treatment of human cancers and other diseases and conditions. In this paper, we report the design, synthesis, and evaluation of γ-carboline-containing compounds as a new class of small-molecule BET inhibitors. The most potent inhibitor (compound 18, RX-37) obtained from this study binds to BET bromodomain proteins (BRD2, BRD3, and BRD4) with Ki values of 3.2-24.7 nM and demonstrates high selectivity over other non-BET bromodomain-containing proteins. Compound 18 potently and selectively inhibits cell growth in human acute leukemia cell lines harboring the rearranged mixed lineage leukemia 1 gene. We have determined a cocrystal structure of 18 in complex with BRD4 BD2 at 1.4 ? resolution, which provides a solid structural basis for the compounds high binding affinity and for its further structure-based optimization. Compound 18 represents a promising lead compound for the development of a new class of therapeutics for the treatment of human cancer and other conditions.

BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME

Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.

Pyrazole derivatives

This invention relates to the use of pyrazole derivatives of the formula and pharmaceutically acceptable salts and solvates thereof, in the manufacture of a reverse transcriptase inhibitor or modulator, to certain novel such pyrazole derivatives and to processes for the preparation of and compositions containing such novel derivatives.